Phase 3 trial finds semaglutide improves BMI category in children 6 to 11
The pediatric readout extends semaglutide obesity data below the adolescent age range where it is already approved.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 8 03:00 ETSource: contemporarypediatrics.com
The wire
- 01A phase 3 trial reported that semaglutide shifted BMI category in children aged 6 to 11 years with obesity.
- 02Pediatric prescribers have had little randomized evidence in this age band, and the result bears on future label expansion for younger patients.
- 03Full safety, durability and growth data, plus regulatory review, will determine whether practice changes for this age group.
From the source
Read at contemporarypediatrics.comSemaglutide improves BMI category in children aged 6 to 11 years in phase 3 trial